Celyad Oncology SA
CLYYF
$0.65
-$0.03-4.41%
OTC PK
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
There are no news to display.
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, April 4, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Sep 8 and 12 (est)
Price History
Beta
--
7-Day Total Return
--
30-Day Total Return
--
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
--
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
-- - --
52-week High
-- - --
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
--
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
32 1 039 41 00
Address
Rue André Dumont 9
Mont-Saint-Guibert, 1435
Mont-Saint-Guibert, 1435
Country
Year Founded
Business Description
Sector
Celyad Oncology SA, a biotechnology company, focuses on research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is developing shRNA non-gene-edited...
more